Juniper Pharmaceuticals Inc (JNP)

NASDAQ

Currency in USD

11.500

0.000(0.00%)

Closed·13/08

Day's Range

11.450

11.500

52 wk Range

0.000

11.500

JNP Income Statement

Featured here, the Income Statement (earnings report) for Juniper Pharmaceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2008

31/12

2009

31/12

2010

31/12

2011

31/12

2012

31/12

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

Total Revenues

aa.aa

27.28

33.39

38.29

54.57

49.98

Total Revenues Growth

aa.aa

+5.63%

+22.39%

+14.66%

+42.54%

-8.42%

Cost Of Revenues

aa.aa

13.25

17.69

21.41

24.29

28.96

Gross Profit

aa.aa

14.03

15.7

16.87

30.28

21.02

Gross Profit Growth

aa.aa

+7.62%

+11.91%

+7.44%

+79.46%

-30.59%

Gross Profit Margin %

aa.aa

51.43%

47.03%

44.07%

55.49%

42.05%

Other Operating Expenses, Total

aa.aa

8.48

10.96

18.75

24.1

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-9.24%	+29.28%	+71.04%	+33.37%	-3.59%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	0.66	7.04	9.68	6.86
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	8.48	10.3	11.71	15.33	17.24
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

5.56

4.74

-1.87

5.28

-3.09

Operating Income Growth

aa.aa

+50.18%

-14.6%

-139.48%

+381.85%

-158.46%

EBIT Margin %

aa.aa

20.36%

14.21%

-4.89%

9.67%

-6.17%

Net Interest Expenses

aa.aa

0.05

-0.12

-0.11

-0.1

-0.13

Net Interest Expenses Growth

aa.aa

-77.31%

-318.52%

+10.17%

+8.49%

-34.02%

Interest Expense, Total

aa.aa

-0.03

-0.12

-0.11

-0.1

-0.13

Interest And Investment Income

aa.aa

0.08

Other Non Operating Expenses, Total

aa.aa

0.78

0.68

0.49

0.86

1.75

EBT, Excl. Unusual Items

aa.aa

6.39

5.31

-1.49

6.04

-1.47

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

0.3

EBT, Incl. Unusual Items

aa.aa

5.08

5.31

-1.49

6.04

-2.25

EBT, Incl. Unusual Items Growth

aa.aa

-48.76%

+4.41%

-128.09%

+505.23%

-137.17%

EBT, Incl. Unusual Items Margin

aa.aa

18.63%

15.89%

-3.89%

11.07%

-4.49%

Income Tax Expense

aa.aa

0.34

0.65

0.01

0.09

-0.19

Net Income to Company

aa.aa

4.74

4.66

-1.5

5.95

-2.06

Minority Interest

aa.aa

Net Income

aa.aa

4.74

4.66

-1.5

5.95

-2.06

Net Income Growth

aa.aa

-52.19%

-1.79%

-132.13%

+497.79%

-134.62%

Net Income Margin %

aa.aa

17.38%

13.94%

-3.91%

10.9%

-4.12%

Preferred Dividend and Other Adjustments

aa.aa

0.03

-0.45

Net Income to Common Excl. Extra Items

aa.aa

4.71

4.63

-1.52

5.92

-1.62

Basic EPS - Continuing Operations

aa.aa

0.42

-0.14

0.55

-0.15

Basic EPS - Continuing Operations Growth

aa.aa

-53.8%

+0.58%

-133.6%

+487.89%

-127.19%

Diluted EPS - Continuing Operations

aa.aa

0.35

0.39

-0.14

0.55

-0.15

Diluted EPS - Continuing Operations Growth

aa.aa

+32.56%

+10.98%

-136.4%

+486.29%

-127.45%

Basic Weighted Average Shares Outstanding

aa.aa

11.26

10.99

10.77

10.8

10.82

Diluted Weighted Average Shares Outstanding

aa.aa

11.27

11.01

10.77

10.89

10.82

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

6.47

6.74

0.04

7.18

-0.83

EBITDA Growth

aa.aa

+49.14%

+4.05%

-99.44%

+18,789.47%

-111.6%

EBITDA Margin %

aa.aa

23.73%

20.17%

0.1%

13.15%

-1.67%

EBIT

aa.aa

5.56

4.74

-1.87

5.28

-3.09

* In Millions of USD (except for per share items)

South Africa Top 40

83,413.69

+156.25

+0.19%

S. Africa 40 Futures

84,137.00

+720

+0.86%

US 30

40,126.50

+33.1

+0.08%

US 500

5,526.40

+41.6

+0.76%

US Tech 100

19,446.80

+232.4

+1.21%

DAX Futures

22,516.90

+289.9

+1.30%

Dollar Index

99.37

+0.200

+0.20%

Market Movers

Name	Last	Chg. %	Vol.
FirstRand Ltd	7,150	+0.56%	10.79M
Harmony Gold Mining Company	28,625	-4.50%	2.82M
Gold Fields	40,667	-3.05%	2.68M
Anglo American	53,405	-0.45%	1.43M
AngloGold Ashanti ADR	74,497	-1.07%	1.27M
Naspers	489,908	+2.45%	518.74K
Capitec	345,288	+1.85%	424.91K

Name	Last	Chg. %	Vol.
MC Mining	136	+18.26%	1.14K
Investec Pref	10,500	+10.54%	13.46K
Famous Brands	5,700	+7.20%	138.99K
Kore Potash	60.00	+7.14%	1.58M
York Timber Holdings Ltd	209	+6.63%	4.72K
Kap Industrial	277	+6.54%	4.33M
Nutun	197	+6.49%	471.82K

Name	Last	Chg. %	Vol.
YeboYethu	2,000	-9.09%	4.48K
Assura	1,230.00	-8.21%	96.42K
Impala Platinum	11,014	-6.02%	4.74M
Aveng Ltd	644	-5.29%	104.72K
Grand Parade	275	-5.17%	16.85K
Lesaka Tech	8,018	-4.99%	6.97K
Northam Platinum Holdings	11,941.00	-4.88%	3.77M

Trending Stocks

Name	Last	Chg. %	Vol.
Aspen Pharmacare	12,022	+1.20%	2.08M
Harmony Gold Mining Company	28,625	-4.50%	2.82M
Capitec	345,288	+1.85%	424.91K
Sasol	6,564	+0.69%	2.53M
Sibanye Stillwater	2,104	-3.88%	13.94M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaa Aaaaaaa	15,801	+55.62%	24,589.52
Aaaaa Aa Aaaaa	15,336	+39.42%	21,381.45
A Aaaa Aaaaaaa	6,695	+35.46%	9,069.05
Aaaaa	13,304	+33.83%	17,804.74
Aaaaaaaaaaaaaaaaa	5,686	+31.43%	7,473.11
Aa Aaaaaaa A	2,525	+30.17%	3,286.79
Aaa Aaaaaaaa	19,639	+28.07%	25,151.67

Name	Last	Upside	Fair Value
Aaa Aaaaaaa	15,801	+55.62%	24,589.52
Aaaaa Aa Aaaaa	15,336	+39.42%	21,381.45
A Aaaa Aaaaaaa	6,695	+35.46%	9,069.05
Aaaaa	13,304	+33.83%	17,804.74
Aaaaaaaaaaaaaaaaa	5,686	+31.43%	7,473.11
Aa Aaaaaaa A	2,525	+30.17%	3,286.79
Aaa Aaaaaaaa	19,639	+28.07%	25,151.67

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Juniper Pharmaceuticals Inc (JNP)

JNP Income Statement

Trending Stocks